As of 10:20 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.2 | -0.2 | -0.83 | -0.72 |
| Low Estimate | -0.24 | -0.23 | -0.93 | -0.94 |
| High Estimate | -0.17 | -0.17 | -0.73 | -0.35 |
| Year Ago EPS | -0.45 | -0.24 | -1.2 | -0.83 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | 1.91M | 1.76M | 6.66M | 20.86M |
| Low Estimate | 1M | 1M | 4M | 8M |
| High Estimate | 3M | 2.87M | 8.45M | 53.85M |
| Year Ago Sales | 3.37M | 744k | 5.72M | 6.66M |
| Sales Growth (year/est) | -43.30% | 136.60% | 16.50% | 213.20% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.24 | -0.23 | -0.25 | -0.21 |
| EPS Actual | -0.45 | -0.24 | -0.25 | -0.22 |
| Difference | -0.21 | -0.01 | 0 | -0.01 |
| Surprise % | -87.50% | -4.30% | 0.00% | -4.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.2 | -0.2 | -0.83 | -0.72 |
| 7 Days Ago | -0.2 | -0.2 | -0.83 | -0.72 |
| 30 Days Ago | -0.19 | -0.19 | -0.8 | -0.66 |
| 60 Days Ago | -0.2 | -0.21 | -0.83 | -0.74 |
| 90 Days Ago | -0.2 | -0.21 | -0.83 | -0.74 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ABSI | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 55.60% | -- | -- | 7.70% |
| Next Qtr. | 16.70% | -- | -- | 11.00% |
| Current Year | 30.80% | -- | -- | 5.00% |
| Next Year | 13.30% | -- | -- | 12.10% |
| Next 5 Years (per annum) | 23.30% | -- | -- | 11.47% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/15/2024 |
| Maintains | Truist Securities: Buy to Buy | 3/26/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/22/2024 |
| Initiated | Scotiabank: Sector Outperform | 3/14/2024 |
| Reiterates | Truist Securities: Buy to Buy | 3/6/2024 |
| Maintains | Keybanc: Overweight to Overweight | 3/4/2024 |
Related Tickers
PRME Prime Medicine, Inc.
5.19
+2.17%
EXAI Exscientia plc
5.23
-1.32%
RLAY Relay Therapeutics, Inc.
6.24
-0.32%
SANA Sana Biotechnology, Inc.
5.24
-0.19%
EWTX Edgewise Therapeutics, Inc.
17.47
-0.06%
RXRX Recursion Pharmaceuticals, Inc.
7.01
-20.03%
ABCL AbCellera Biologics Inc.
2.7900
0.00%
NRIX Nurix Therapeutics, Inc.
20.95
+2.39%
SLDB Solid Biosciences Inc.
5.86
+2.81%
WVE Wave Life Sciences Ltd.
4.6000
+5.13%